The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

European shares were broadly flat on Monday, as investors refrained from making big bets ahead of a key U.S. inflation data, ...

Packaged breads and refined grain products may increase the odds of developing IBD, while minimally processed fresh bread and ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Novartis' mAb ianalumab helped maintain safe platelet levels for a prolonged period, reducing patient reliance on hospital ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Roche (RHHBY) and Novartis (NVS) are scheduled to meet with Swiss officials this week amid U.S. tariff threats on pharma ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Novartis has been evaluating a bid for Avidity, which had a market value of about $5.8bn at market close on Wednesday, and ...